Information on the clinical trials we are and have been involved in.
As our mechanistic understanding of the modes of action of hyperbaric oxygen (HBO) therapy improves, new potential applications for the therapy will emerge. We at DDRC Healthcare are committed to performing clinical trials as part of our research portfolio in order to determine which clinical conditions are likely to benefit from this mode of treatment.
HOPON Trial - HBO & Osteoradionecrosis for Head & Neck Cancer
DDRC Healthcare is one of the centres providing hyperbaric oxygen to patients selected to the treatment arm of a multicentre randomised trial on HBO for the prevention of osteoradionecrosis (HOPON). Patients who have received radiotherapy for head and neck cancer are at risk of developing osteoradionecrosis particularly following dental extraction in the irradiated area. This condition has a significant effect on quality of life and health, by causing pain and difficulty in eating. This study is being coordinated by the Liverpool Cancer Trials Unit and is supported by Cancer Research UK. It has been running since 2008.
HOT II - HBO & Long-Term Effects of Radiotherapy for Pelvic Cancer
The HOTII study, which is lead by the Royal Marsden Hospital in London, is a multicentre double blind randomised controlled trial investigating hyperbaric oxygen (HBO) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer. These side effects can result in patients feeling unable to go about their day-to-day lives. The trial involved randomising patients to receive either hyperbaric oxygen or sham treatments. They were not aware of which arm of the trial they were on. The study commenced in 2008 and all participants have been treated with follow up data now being collected and the Clinical Study Report will be available soon.
Other completed clinical trials in which we were involved include the HOT study, which was a multicentre trial investigating the effect of HBO on arm lymphoedema, a condition of severe and often debilitating swelling developed by some women after radiotherapy for breast cancer. This trial was again led by the Royal Marsden Hospital in London, world renowned for its cancer research.